key: cord-0734859-h4d571ny authors: da Fonseca, Leonardo; Carrilho, Flair José title: Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS‐Cov‐2? date: 2020-05-30 journal: Liver Int DOI: 10.1111/liv.14545 sha: dde9b9b414204f8490c681a4678fa20c43f05763 doc_id: 734859 cord_uid: h4d571ny We read with interest the editorial by Sharma and Pinato on the management of hepatocellular carcinoma (HCC) in the time of SARS-Cov-2 (1). The points raised by the authors will be of paramount importance to guide HCC groups worldwide. Can thrombotic events be a major concern in hepatocellular carcinoma patients under systemic treatment during SARS-Cov-2? To the Editor We read with interest the editorial by Sharma and Pinato on the management of hepatocellular carcinoma (HCC) in the time of SARS-Cov-2. 1 The points raised by the authors will be of paramount importance to guide HCC groups worldwide. Once there is no evidence suggesting that tyrosine kinase inhibitors (TKIs) increase the risk of COVID-19, the balance favours towards continuing TKIs for advanced-HCC patients who are likely to benefit from treatment. The approach to treat with a 50% dose LGdF has received lectures fees from Bayer and Roche. Management of hepatocellular cancer in the time of SARS-CoV-2 Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and metaanalysis Mechanisms of adverse effects of anti-VEGF therapy for cancer